Health care costs associated with hepatocellular carcinoma: A population‐based study

Hla‐Hla Thein, Wanrudee Isaranuwatchai, Michael A. Campitelli, Jordan J. Feld, Eric Yoshida, Morris Sherman, Jeffrey S. Hoch, Stuart Peacock, Murray D. Krahn, Craig C. Earle – 8 January 2013 – Although the burden of hepatocellular carcinoma (HCC) is an escalating public health problem, it has not been rigorously estimated within a Canadian context. We conducted a population‐based study using Ontario Cancer Registry linked administrative data. The mean net costs of care due to HCC were estimated using a phase of care approach and generalized estimating equations.

p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver

Svitlana Kurinna, Sabrina A. Stratton, Zeynep Coban, Jill M. Schumacher, Markus Grompe, Andrew W. Duncan, Michelle Craig Barton – 8 January 2013 – Functions of p53 during mitosis reportedly include prevention of polyploidy and transmission of aberrant chromosomes. However, whether p53 plays these roles during genomic surveillance in vivo and, if so, whether this is done via direct or indirect means remain unknown. The ability of normal, mature hepatocytes to respond to stimuli, reenter the cell cycle, and regenerate liver mass offers an ideal setting to assess mitosis in vivo.

Immunoglobulin G4+ clones identified by next‐generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis

Lucas J. Maillette de Buy Wenniger, Marieke E. Doorenspleet, Paul L. Klarenbeek, Joanne Verheij, Frank Baas, Ronald P. Oude Elferink, Paul P. Tak, Niek de Vries, Ulrich Beuers – 8 January 2013 – Immunoglobulin G4 (IgG4)‐associated cholangitis (IAC) is a manifestation of the recently discovered idiopathic IgG4‐related disease. The majority of patients have elevated serum IgG4 levels and/or IgG4‐positive B‐cell and plasma cell infiltrates in the affected tissue.

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid‐induced liver injury in superobese patients with nonalcoholic steatohepatitis

Lars P. Bechmann, Peri Kocabayoglu, Jan‐Peter Sowa, Svenja Sydor, Jan Best, Martin Schlattjan, Anja Beilfuss, Johannes Schmitt, Rebekka A. Hannivoort, Alpaslan Kilicarslan, Christian Rust, Frieder Berr, Oliver Tschopp, Guido Gerken, Scott L. Friedman, Andreas Geier, Ali Canbay – 8 January 2013 – Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in industrialized countries and may proceed to steatohepatitis (NASH). Apoptosis and free fatty acid (FFA)‐induced lipotoxicity are important features of NASH pathogenesis.

Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models

Stephanie Coulon, Vanessa Legry, Femke Heindryckx, Christophe Van Steenkiste, Christophe Casteleyn, Kim Olievier, Louis Libbrecht, Peter Carmeliet, Bart Jonckx, Jean‐Marie Stassen, Hans Van Vlierberghe, Isabelle Leclercq, Isabelle Colle, Anja Geerts – 8 January 2013 – The pathophysiology of nonalcoholic steatohepatitis (NASH) should be approached as a multifactorial process. In several stages of NASH, a link between disease progression and hepatic microvasculature changes can be made.

Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C

Michael R. Kraus, Arne Schäfer, Gerlinde Teuber, Heiner Porst, Kathrin Sprinzl, Sven Wollschläger, Christian Keicher, Michael Scheurlen – 8 January 2013 – Earlier studies have suggested neurocognitive impairment in patients with chronic hepatitis C virus (HCV) infection even before liver cirrhosis has developed. Since these deficits might be reversible after successful antiviral therapy, we analyzed the long‐term course of neurocognitive parameters in HCV patients with and without successful virus elimination by an interferon‐based antiviral treatment.

Subscribe to